Chemoimmunotherapy Linked to HNSCC Response - Report - MDSpire

Chemoimmunotherapy Linked to HNSCC Response

  • By

  • Andrea Surnit

  • June 5, 2026

Share

Clinical Report: Chemoimmunotherapy Linked to HNSCC Response

Overview

Neoadjuvant chemoimmunotherapy demonstrated higher pathologic and radiographic response rates compared to neoadjuvant immunotherapy alone in patients with resectable head and neck squamous cell carcinoma (HNSCC).

Background

The treatment of head and neck squamous cell carcinoma (HNSCC) is evolving, with neoadjuvant therapies being explored to improve outcomes. This systematic review and meta-analysis provides insights into the efficacy of combining chemotherapy with immunotherapy in resectable cases.

Data Highlights

TreatmentMPR + CPR RateCPR RateRadiographic Response Rate
Chemoimmunotherapy66%38%66%
Dual-Agent Immunotherapy18%5%9%
Single-Agent Immunotherapy6%3%6%

Key Findings

  • Pooled MPR plus CPR rates were 66% among patients treated with chemoimmunotherapy.
  • CPR rates were 38% for chemoimmunotherapy, compared to 5% for dual-agent and approximately 3% for single-agent immunotherapy.
  • 78% of patients receiving single-agent immunotherapy showed no pathologic response.
  • Radiographic response rates favored chemoimmunotherapy, with 66% showing partial or complete responses.
  • Adverse events were reported inconsistently, with grade 3 to 5 events occurring in 17% of the chemoimmunotherapy group.
  • 2% of single-agent, 12% of dual-agent, and 15% of chemoimmunotherapy patients did not proceed to surgery after treatment.

Clinical Implications

The findings suggest that neoadjuvant chemoimmunotherapy may enhance pathologic responses in resectable HNSCC, but the variability in patient outcomes and adverse event reporting necessitates careful consideration in clinical decision-making. Further studies are warranted to clarify the role of this treatment approach.

Conclusion

Further research is needed to establish the definitive role and impact on survival outcomes.

Related Resources & Content

  1. The ASCO Post, 2025 -- Targeted Therapy in the Age of Immunotherapy in Head and Neck Cancer
  2. The ASCO Post, 2025 -- Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer
  3. The ASCO Post, 2025 -- Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
  4. Frontiers in Oncology, 2026 -- Dual-energy and perfusion CT for predicting response to chemo-radiotherapy in head and neck cancer: an exploratory study
  5. FDA -- FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
  6. PubMed -- Neoadjuvant Immunotherapy in Resectable HNSCC: An Updated Systematic Review and Meta-analysis
  7. FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma | FDA
  8. Neoadjuvant Immunotherapy in Resectable HNSCC: An Updated Systematic Review and Meta-analysis - PubMed

Original Source(s)

Chemoimmunotherapy Linked to HNSCC Response

  • by Andrea Surnit

  • June 5, 2026

Related Content

Platelet-Rich Plasma Reduces Pain After Tonsillectomy

Randomized trial shows reduced postoperative pain and faster mucosal healing without increased bleeding risk

Oral and Head and Neck Cancers Rising: What You Need to Know

Most people know that tobacco use is a major risk factor for oral and head and neck cancers. Some even understand that excessive alcohol consumption also ups the odds.

  • April 6, 2026

  • 7 min
Real-world healthcare resource use and costs associated with the management of locally advanced head and neck cancer in Portugal – TRACE2 study